NAGIOS: RODERIC FUNCIONANDO
Control of drooling using transdermal scopolamine skin patches : a case report
Repositori DSpace/Manakin
- Inici
- Investigació
- Revistes
- Medicina oral, patología oral y cirugía bucal. Ed inglesa
- Medicina oral, patología oral y cirugía bucal. Ed inglesa. 2008. Vol. 13, no. 1
- Visualitza element
IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/
Control of drooling using transdermal scopolamine skin patches : a case report
Mostra el registre parcial de l'element
| dc.contributor.author | Mato Montero, Abigail | es |
| dc.contributor.author | Limeres Posse, Jacobo | es |
| dc.contributor.author | Tomás Carmona, Inmaculada | es |
| dc.contributor.author | Fernández Feijoo, Javier | es |
| dc.contributor.author | Diz Dios, Pedro | es |
| dc.date.accessioned | 2017-09-11T07:43:25Z | |
| dc.date.available | 2017-09-11T07:43:25Z | |
| dc.date.issued | 2008 | es |
| dc.identifier.citation | Mato Montero, Abigail ; Limeres Posse, Jacobo ; Tomás Carmona, Inmaculada ; Fernández Feijoo, Javier ; Diz Dios, Pedro. Control of drooling using transdermal scopolamine skin patches : a case report. En: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, 13 1 2008: 6- | es |
| dc.identifier.uri | http://hdl.handle.net/10550/60657 | |
| dc.description.abstract | Transdermal scopolamine has been shown to be very useful in the management of drooling, particularly in patients with neurological or neuropsychiatric disturbances or severe developmental disorders. In this paper, we present the case of a 24-year-old patient with a diagnosis of cerebral palsy and a severe problem of drooling, exacerbated by marked mandibular prognathism. After exclusion of other therapeutic alternatives, it was decided to use sustainedrelease transdermal scopolamine patches (Scopoderm TTS). This technique consists of the application every three days of a patch with 1.5 mg of scopolamine in the area of the mastoid apophysis; the patch releases a dose of 0.5 mg of the active substance over each 24 hour period. The patient underwent periodic clinical and laboratory follow-up over a period of three years, achieving satisfactory results with no significant undesirable effects. | es |
| dc.title | Control of drooling using transdermal scopolamine skin patches : a case report | es |
| dc.type | journal article | es_ES |
| dc.subject.unesco | UNESCO::CIENCIAS MÉDICAS | es |
| dc.identifier.doi | es | |
| dc.type.hasVersion | VoR | es_ES |
Visualització
(161.4Kb)